Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9606634 | 0.84 | PIK3CA (0.33) | HTTRECQLPIK3CANOS3NOS1 | |
| SCHEMBL10085335 | 0.83 | KMT2A (0.34) | HTTRECQL | |
| SCHEMBL22477468 | 0.82 | LRRK2 (0.33) | — | |
| SCHEMBL25911621 | 0.78 | P2RX3 (0.36) | HTTRECQLPIK3CANOS3NOS1 | |
| SCHEMBL30068288 | 0.78 | P2RX3 (0.36) | HTTRECQLPIK3CANOS3NOS1 | |
| SCHEMBL6129987 | 0.76 | NOS3 (0.35) | NOS3NOS1NOS2 | |
| SCHEMBL30585581 | 0.76 | NOS3 (0.35) | NOS3NOS1NOS2 | |
| SCHEMBL6124109 | 0.76 | PDCD1 (0.38) | — | |
| SCHEMBL19407622 | 0.74 | P2RX3 (0.30) | — | |
| SCHEMBL84915 | 0.74 | P2RX3 (0.36) | PIK3CANOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | HTT 1976/4885RECQL 1980/4885PIK3CA 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.